Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion

被引:4
作者
Saji, K [1 ]
Sakuma, M [1 ]
Suzuki, J [1 ]
Takahashi, T [1 ]
Demachi, J [1 ]
Nawata, J [1 ]
Kitamukai, O [1 ]
Onoue, N [1 ]
Sugimura, K [1 ]
Tada, T [1 ]
Fukui, S [1 ]
Kagaya, Y [1 ]
Watanabe, J [1 ]
Shirato, K [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Aoba Ku, Sendai, Miyagi 9808574, Japan
关键词
epoprostenol; fractional pulse pressure; nitric oxide; pulmonary angiography; pulmonary arterial hypertension;
D O I
10.1253/circj.69.335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background There have only been a few reports published on combination therapy for patients with primary pulmonary hypertension (PPH). Methods and Results Fifteen patients with PPH (4 men and 11 women, 34.5 +/- 12.1 years old) had received chronic administration of epoprostenol and the additive effects of inhaled nitric oxide (NO) and the hemodynamic changes were evaluated. In addition, the difference in the effect of acute NO loading before and after the epoprostenol therapy was compared in 6 of these patients. Under chronic use of epoprostenol, mean pulmonary arterial pressure, mean right atrial pressure and pulmonary vascular resistance were decreased with acute inhalation of NO. However, cardiac output, mean aortic pressure and systemic vascular resistance were unchanged. As a result. the pulmonary to systemic vascular resistance ratio was reduced. Moreover, after chronic use of epoprostenol, the change (delta) in cardiac output with NO inhalation was increased and the NO-induced decrease in pulmonary vascular resistance was augmented compared to those before the induction. Conclusion Nitric oxide inhalation further improved the hemodynamics when combined with chronic use of epoprostenol in PPH patients. These results suggest the possibility that combination therapies can be used in the treatment for PPH patients.
引用
收藏
页码:335 / 338
页数:4
相关论文
共 30 条
[1]   A new era in the treatment of primary pulmonary hypertension [J].
Bailey, CL ;
Channick, RN ;
Rubin, LJ .
HEART, 2001, 85 (03) :251-252
[2]   Beraprost therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
McLaughlin, V ;
Tapson, V ;
Oudiz, R ;
Shapiro, S ;
Robbins, IM ;
Channick, R ;
Badesch, D ;
Rayburn, BK ;
Flinchbaugh, R ;
Sigman, J ;
Arneson, C ;
Jeffs, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125
[3]   Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin [J].
Barst, RJ .
HEART, 1997, 77 (04) :299-301
[4]   Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension [J].
Castelain, V ;
Chemla, D ;
Humbert, M ;
Sitbon, O ;
Simonneau, G ;
Lecarpentier, Y ;
Hervé, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (03) :338-340
[5]   Bosentan therapy for pulmonary arterial hypertension [J].
Cohen, H ;
Chahine, C ;
Hui, A ;
Mukherji, R .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (11) :1107-1119
[6]   Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].
Deng, ZM ;
Morse, JH ;
Slager, SL ;
Cuervo, N ;
Moore, KJ ;
Venetos, G ;
Kalachikov, S ;
Cayanis, E ;
Fischer, SG ;
Barst, RJ ;
Hodge, SE ;
Knowles, JA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744
[7]   Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension [J].
Ghofrani, HA ;
Pepke-Zaba, J ;
Barbera, JA ;
Channick, R ;
Keogh, AM ;
Gomez-Sanchez, MA ;
Kneussl, M ;
Grimminger, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :68S-72S
[8]   Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension [J].
Ghofrani, HA ;
Rose, F ;
Schermuly, RT ;
Olschewski, H ;
Wiedemann, R ;
Kreckel, A ;
Weissmann, N ;
Ghofrani, S ;
Enke, B ;
Seeger, W ;
Grimminger, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) :158-164
[9]   Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats [J].
Hill, NS ;
Warburton, RR ;
Pietras, L ;
Klinger, JR .
JOURNAL OF APPLIED PHYSIOLOGY, 1997, 83 (04) :1209-1215
[10]   A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension [J].
Hoeper, MM ;
Olschewski, H ;
Ghofrani, HA ;
Wilkens, H ;
Winkler, J ;
Borst, MM ;
Niedermeyer, J ;
Fabel, H ;
Seeger, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :176-182